Astaxanthin

Astaxanthin: A Comprehensive Encyclopedic Reference

1. Identity: Chemical Name, Structure, and Natural Sources

Chemical Identity

Astaxanthin (3,3′-dihydroxy-β, β′-carotene-4,4′-dione) is a xanthophyll carotenoid belonging to the broader class of terpenoid-derived pigments. It is a keto-carotenoid within a group of chemical compounds known as carotenoids, a subclass of the broad group of phytochemicals known as terpenes, and is a metabolite of zeaxanthin and canthaxanthin, containing both hydroxyl and ketone functional groups. Its molecular formula is C₄₀H₅₂O₄ with a molecular weight of 596.82.

It is a lipid-soluble pigment with red coloring properties, which result from the extended chain of conjugated (alternating double and single) double bonds at the center of the compound. The presence of the hydroxyl functional groups and the hydrophobic hydrocarbons render the molecule amphiphilic. This amphiphilic character is functionally important, as it allows the molecule to span cell membranes and interact with both aqueous and lipid environments.

Stereoisomerism and Ester Forms

Astaxanthin has three isomers of 3S,3S′-form, 3S,3R′-form (meso form) and 3R,3R′-form, which differ in the steric configurations of the hydroxyl groups at the 3(3′)-position of the ring structures. Additionally, cis- and trans-isomers of conjugated double bonds at the molecular center are also present. Depending on its origin, astaxanthin may be esterified with different fatty acids, such as palmitic, oleic, stearic or linoleic acid; it may also be free, with non-esterified hydroxyl groups, but this makes it considerably unstable and particularly susceptible to oxidation.

Astaxanthin can be esterified, which increases its solubility in the cell and makes it more stable to oxidation. The hydroxy group on one or both rings can bind to different fatty acids, such as palmitic, oleic, stearic, or linoleic acid, to form mono- or diesters, accordingly. Astaxanthin also exists in a free form, i.e., with the hydroxyl group not esterified, and in a chemical complex with proteins or lipoprotein.

Primary Natural Sources

Astaxanthin is a xanthophyll carotenoid mainly derived from marine microalgae such as Haematococcus pluvialis and Chlorella zofingiensis, as well as the yeast Phaffia rhodozyma. Natural sources of astaxanthin also include marine bacteria, fungi, higher plants (Adonis species), krill, and microalgae such as Chlorococcum spp. and Dunaliella salina.

The microalgae Haematococcus pluvialis contains high levels of astaxanthin (about 3.8% of dry weight), and is the primary industrial source of natural astaxanthin. When the algae are stressed by lack of nutrients, increased salinity, or excessive sunshine, they create astaxanthin. Animals who feed on the algae, such as salmon, red trout, red sea bream, flamingos, and crustaceans (shrimp, krill, crab, lobster, and crayfish), subsequently reflect the red-orange astaxanthin pigmentation.

Crustaceans and fish cannot synthesize astaxanthin de novo, and thereby rely on the supply of astaxanthin precursors through the consumption of algae and other microorganisms. In shellfish, astaxanthin is almost exclusively concentrated in the shells, with only low amounts in the flesh itself, and most of it only becomes visible during cooking as the pigment separates from the denatured proteins that otherwise bind it. Astaxanthin is also extracted from Euphausia superba (Antarctic krill) and from shrimp processing waste.

Synthetic Production

The commercial market for astaxanthin has shown great potential and is estimated to grow significantly, yet cheap chemical astaxanthin meets approximately 95% of market demand. The primary use of synthetic astaxanthin today is as an animal feed additive to impart coloration, including farm-raised salmon and chicken. Synthetic astaxanthin is different from natural astaxanthin — it is a mixture of stereo-isomers, some of which are not synthesized in nature, are less stable under technological conditions, and have poor bioavailability.

2. Traditional and Historical Use

Astaxanthin as a defined, isolated compound has no documented history of use in ancient or pre-modern medical traditions. It does not appear in classical Ayurvedic, Traditional Chinese Medicine, or Western herbal pharmacopoeias as an identified substance. Its presence in the human diet, however, is ancient and cross-cultural: traditional diets in Nordic countries and Japan unknowingly incorporated astaxanthin via fatty fish and shellfish.

Initially isolated from lobster (Homarus gammarus) hepatopancreas, astaxanthin now constitutes a global market exceeding USD 1 billion. In 1975, astaxanthin's chemical structure was fully characterized, revealing a xanthophyll backbone with hydroxyl and keto groups, which sparked interest in its antioxidant potential. Through the 1980s, it showed promise in aquaculture (coloring farmed salmon) and later in nutraceutical studies on rodents and cell models.

Astaxanthin was first commercially used for pigmentation only in the aquaculture industry to increase astaxanthin content in farmed salmonids and obtain the characteristic orange-red color of the flesh. The initial application of astaxanthin in aquaculture to enhance the coloration of aquatic organisms was reported in 1998. Human nutraceutical use followed in subsequent decades, driven by accumulating evidence of its antioxidant properties rather than by pre-existing traditional medical practice.

Dietary supplements containing Haematococcus astaxanthin have been widely used for over 15 years as a nutraceutical supplement. There is no established ethnobotanical or traditional medicine record that specifically prescribes astaxanthin-containing preparations for therapeutic purposes; its formal use as a health supplement is a product of modern nutritional science.

3. Key Constituents and Active Compounds

Astaxanthin is both the primary compound of interest and the principal active constituent of preparations derived from H. pluvialis. It occurs primarily in esterified form in algal preparations. Astaxanthin is accumulated as a secondary carotenoid and stored in lipid bodies in the forms of mono-ester or di-ester in the red stage of H. pluvialis.

The antioxidant potency of astaxanthin is substantially attributable to its molecular architecture. Astaxanthin contains both a hydroxyl and a keto group, and this unique structure plays important roles in neutralizing reactive oxygen species (ROS). The molecule quenches harmful singlet oxygen, scavenges peroxyl and hydroxyl radicals and converts them into more stable compounds, prevents the formation of free radicals, and inhibits the autoxidation chain reaction.

Astaxanthin is a natural C40 carotenoid with numerous reported biological functions, most of them associated with its antioxidant and anti-inflammatory activity, standing out from other antioxidants as it has shown the highest oxygen radical absorbance capacity (ORAC), 100–500 times higher than α-tocopherol and a 10 times higher free radical inhibitory activity than related antioxidants (α-tocopherol, α-carotene, β-carotene, lutein and lycopene).

4. Mechanisms of Action

Antioxidant Mechanisms

Nrf2 is a cellular sensor of electrophilic stress that coordinates the expression of a battery of defensive genes encoding antioxidant proteins and detoxifying enzymes. Astaxanthin activates this pathway: in addition to direct ROS scavenging, astaxanthin exerts antioxidant effects through regulation of cellular defense systems, with one key mechanism involving the activation of nuclear factor erythroid 2–related factor 2 (Nrf2), a transcription factor that regulates antioxidant response elements and maintains redox homeostasis.

Astaxanthin modulates oxidative stress via the PI3K/Akt-Nrf2 pathway and suppresses NF-κB-mediated inflammatory responses, reducing cytokine levels such as TNF-α, IL-6, and iNOS. NF-κB acts as a mediator of cellular stress and induces the expression of various pro-inflammatory genes, including those encoding cytokines, chemokines, and adhesion molecules. Astaxanthin suppresses this pathway, thereby curtailing downstream inflammatory cascades.

Anti-Inflammatory Mechanisms

Both in vivo and in vitro studies have shown that astaxanthin affords anti-inflammatory and antioxidant efficacies by downregulating NF-κB via both Nrf2-dependent and Nrf2-independent mechanisms. Astaxanthin exerts its anti-inflammatory effect not only by inhibiting nuclear translocation of NF-κB p65 and decreasing the expression of IL-6 and IL-1β but also by reducing cellular ROS accumulation.

Mitochondrial and Apoptotic Effects

Astaxanthin has been shown to modulate mitochondrial function under oxidative stress conditions. Pre-treatment with astaxanthin has been reported to restore mitochondrial membrane potential, reduce hydrogen peroxide-induced apoptosis, and enhance mitochondrial activity in redox-challenged states. Astaxanthin exerts dual apoptotic effects: cytoprotective in non-transformed cells and pro-apoptotic in cancer cells through p53 activation.

Absorption and Pharmacokinetics

Astaxanthin mixes with bile acid after ingestion and forms micelles in the small intestine. These micelles are partially absorbed by intestinal mucosal cells, which incorporate astaxanthin into chylomicra. Chylomicra with astaxanthin are digested by lipoprotein lipase after releasing into the lymph within the systemic circulation, and chylomicron remnants are rapidly removed by the liver and other tissues. Astaxanthin is then assimilated with lipoproteins and transported into the tissues.

Astaxanthin is absorbed in the human gastrointestinal tract. Its bioavailability and distribution seem to depend on a variety of factors, including its form, its mode of consumption and the smoking habits of the consumer. Studies have shown that absorption of astaxanthin is enhanced in the presence of fats, surfactants or phospholipids.

Astaxanthin's clinical application is limited due to low oral bioavailability, primarily caused by its high lipophilicity and low water solubility. Several strategies can be employed to enhance astaxanthin's bioavailability, including novel delivery systems such as lipid-based carriers, nano-delivery with a sustained-release system, and targeted delivery systems, and structural modifications such as esterification and isomer form selection.

Astaxanthin is absorbed from the small intestine, transported to the plasma and erythrocytes, to the brain by crossing the blood-brain barrier, and to the skin including the epidermis and dermis. This ability to cross the blood-brain and blood-retinal barriers is considered a particularly notable pharmacokinetic property compared with other carotenoids.

5. Scientific Evidence by Area of Use

5.1 Oxidative Stress and General Antioxidant Capacity

The strongest and most consistent human clinical evidence for astaxanthin is its capacity to reduce systemic oxidative stress biomarkers. Fifteen studies involving human participants have been included in a recent systematic review, with astaxanthin consistently reducing pro-inflammatory cytokines (IL-6, TNF-α, TGF-β1) and oxidative stress indices while increasing antioxidant capacity (SOD, TAC).

Cardiometabolic and respiratory outcomes in human trials showed improved endothelial function and reduced disease severity. Astaxanthin demonstrates broad antioxidant and anti-inflammatory properties, supporting its role as a promising adjunctive therapy for metabolic, reproductive, and cardiovascular health, though further well-designed clinical trials are needed to confirm optimal dosing and mechanisms of action.

5.2 Cardiovascular Health

Astaxanthin is a xanthophyll carotenoid with potent antioxidant and anti-inflammatory effects demonstrated in both experimental and human studies. Oxidative stress and inflammation are common pathophysiological features of atherosclerotic cardiovascular disease, hence astaxanthin may have a potential therapeutic role in this condition.

The safety, bioavailability and effects of astaxanthin on oxidative stress and inflammation that have relevance to the pathophysiology of atherosclerotic cardiovascular disease have been assessed in a small number of clinical studies. No adverse events have been reported and there is evidence of a reduction in biomarkers of oxidative stress and inflammation with astaxanthin administration. Experimental studies in several species using an ischaemia-reperfusion myocardial model demonstrated that astaxanthin protects the myocardium when administered both orally or intravenously prior to the induction of the ischaemic event. However, as of early reviews, it was not known whether astaxanthin is of benefit when administered after a cardiovascular event and no definitive clinical cardiovascular studies in humans had been completed and/or reported.

Regarding lipid profiles, one meta-analysis assessment showed a decrease in triglyceride levels from 151 ± 26 mg/dL pre-intervention to 112 ± 40 mg/dL post-intervention (p < 0.01) for an 18 mg/day astaxanthin supplementation dose. Cardiometabolic outcomes in human trials also showed improved endothelial function. Overall, the cardiovascular evidence base remains preliminary; most findings derive from small trials and further large, controlled trials are warranted.

5.3 Skin Health and Photoprotection

Due to its collective diverse functions in skin biology, there is mounting evidence that astaxanthin possesses various health benefits and important nutraceutical applications in the field of dermatology. The effects of astaxanthin on hyperpigmentation suppression, melanin synthesis and photoaging inhibition, and wrinkle formation reduction have been reported in several clinical studies.

Clinical studies show that oral astaxanthin (typically 4–12 mg/day for 8–16 weeks) can reduce UV-induced erythema, improve skin moisture, and support barrier function. Mechanistic studies demonstrate that astaxanthin suppresses UV-induced matrix metalloproteinase-1 (MMP-1) expression and inflammatory cytokine release, thereby limiting collagen degradation. Systematic reviews and meta-analyses indicate moderate but consistent improvements in skin elasticity and hydration, while effects on wrinkle depth are more variable and study-dependent.

One notable randomized, double-blind, placebo-controlled study involved 65 healthy female participants for 16 weeks to investigate the in vivo effect of oral astaxanthin supplementation. Subjective skin conditions for "improvement of rough skin" and "texture" in non-irradiated areas were significantly improved by astaxanthin. Astaxanthin appears protective against UV-induced skin deterioration and helps maintain healthy skin in healthy people.

Astaxanthin disrupts the activity of enzymes such as peroxidase, flavin light synthase, and tyrosinase, thereby reducing melanin deposition and the formation of pigmented spots. Melanin deposition is another contributing factor to skin photoaging, and the inhibitory effect of astaxanthin can alleviate these adverse reactions and improve the photoaging condition of the skin. However, a more recent systematic review and meta-analysis found that there is currently insufficient evidence to support the recommendation of astaxanthin for the treatment of skin photoaging specifically, underscoring the need for larger trials.

5.4 Eye Health

Benefits on eye health promotion have been reported, highlighting its potential for the prevention of skin photo-aging and the treatment of eye diseases like glaucoma, cataracts and uveitis. Supplementation with astaxanthin (typically 4–9 mg/day) has been shown to improve markers of oxidative balance in ocular tissues and enhance visual performance in adults exposed to prolonged work at visual display terminals.

Unlike beta-carotene, astaxanthin is able to readily cross the blood-brain barrier and protect the retina against photo-oxidation and loss of photoreceptor cells. Astaxanthin has not been shown to crystallize in the retina, though this has been reported to cause asymptomatic indications with canthaxanthin in the past. Human clinical evidence in the ocular domain remains limited to small trials primarily assessing visual fatigue and oxidative markers; large-scale randomized trials for age-related macular degeneration or glaucoma treatment in humans are lacking.

5.5 Cognitive Function and Neuroprotection

In vitro and in vivo studies have associated astaxanthin's unique molecular features with several health benefits, including neuroprotective properties, suggesting its therapeutic potential for the prevention or co-treatment of dementia, Alzheimer's disease, and Parkinson's disease.

At the clinical level, human randomized controlled trials report modest improvements in memory and psychomotor performance with doses of 6–12 mg/day for 8–12 weeks, particularly in middle-aged and older adults. These cognitive effects are accompanied by improvements in systemic oxidative markers, suggesting that enhanced redox balance may contribute to observed functional outcomes. Evidence for disease-modifying effects in neurodegenerative disorders remains preliminary, with current support derived mainly from animal models and small human trials.

A systematic review of RCTs found that five studies using lutein and two studies using astaxanthin met inclusion criteria for cognitive function outcomes. Overall, the cognitive evidence base for astaxanthin alone is small and findings should be considered preliminary.

5.6 Exercise Performance and Muscle Recovery

Combined astaxanthin and exercise interventions in human studies improved body composition, lipid profiles, insulin sensitivity, and immune recovery. A randomized, double-blind, placebo-controlled trial assessed exercise performance directly: twenty-two male participants received placebo or astaxanthin (12 mg/day orally) for 30 days and were tested pre- and post-supplementation with a maximal oxygen uptake (VO₂ Max) test and a heat tolerance test (2-hour walk at 40°C, 40% relative humidity). This study found that astaxanthin improved aerobic exercise recovery without affecting heat tolerance.

5.7 Metabolic and Glycemic Health

Preclinical and clinical findings have demonstrated benefits in conditions such as nonalcoholic fatty liver disease and hypertension. Combined astaxanthin and exercise interventions improved body composition, lipid profiles, and insulin sensitivity in human subjects. Evidence in this domain remains largely from small trials, and larger confirmatory studies are needed.

5.8 Reproductive Health

In women with polycystic ovary syndrome (PCOS) or endometriosis, astaxanthin supplementation downregulated endoplasmic reticulum stress–related apoptotic pathways and improved oocyte and embryo quality in human studies.

Regarding male fertility, a recent systematic review and meta-analysis reported a notably discordant finding: ten studies met the inclusion criteria (three clinical trials and seven animal studies), and the human meta-analysis showed no statistically significant improvements in any semen parameters compared with placebo, indicating very limited and low-certainty clinical evidence. In contrast, animal studies demonstrated clear and significant improvements in sperm count, motility, viability, and morphology, along with reductions in oxidative stress markers. In conclusion, astaxanthin shows clear reproductive benefits in animal models, but the meta-analysis found no significant effects on male semen parameters in humans.

5.9 Immune Function

The role of astaxanthin in regulating immune responses has been described, with a special focus on its ability to reduce inflammation and reactive oxygen species (ROS), resulting in several other health benefits. Human evidence on immune modulation is modest and generally derived from secondary outcomes in trials designed primarily for other endpoints. Astaxanthin supplementation consistently reduced pro-inflammatory cytokines (IL-6, TNF-α, TGF-β1) in human studies.

6. Body Systems Associated with Astaxanthin

• Cardiovascular system: Antioxidant and anti-inflammatory activity at the vascular level; preliminary evidence of improvements in lipid profiles and endothelial function.
• Integumentary system (skin): Photoprotection, reduction of UV-induced oxidative damage, modulation of MMP-1 and melanin synthesis, improvements in skin moisture and elasticity.
• Visual system (eyes): Crosses the blood-retinal barrier; antioxidant protection of retinal tissue; improvement of visual fatigue markers.
• Central nervous system (brain): Crosses the blood-brain barrier; preliminary clinical evidence of modest improvements in memory and cognitive performance in older adults.
• Musculoskeletal system: Reduction of exercise-induced oxidative stress; improved post-exercise recovery in clinical trials.
• Metabolic/endocrine system: Preliminary evidence for improvements in insulin sensitivity, lipid profiles, and liver health markers.
• Reproductive system: Clinical improvements in oocyte quality in women with PCOS or endometriosis; male fertility effects not confirmed in human meta-analyses despite positive animal data.
• Immune system: Reduction of pro-inflammatory cytokines in human studies; modulation of oxidative stress-linked immune pathways.

7. Dosage Forms and Reported Dosages

Forms Available

Astaxanthin is used as a dietary supplement for human, animal, and aquaculture consumption. For human use, it is commercially available in softgel capsules, hard-shell capsules, tablets, and powder forms, typically as an oleoresin derived from H. pluvialis biomass. Haematococcus pluvialis-derived astaxanthin in the all-E-3S-3′S form is the most common type used as a dietary supplement and in clinical trials.

The cosmetic industry also benefits from astaxanthin's ability to combat oxidative damage, improve skin elasticity, and reduce signs of aging, leading to its incorporation into advanced skincare formulations.

Dosages Reported in Clinical Studies

• Natural astaxanthin from H. pluvialis or krill oil is available in the market as a dietary supplement in dosages from 3.8 to 7.6 mg per day due to potential health benefits.
• Oral astaxanthin at typically 4–12 mg/day for 8–16 weeks was used in clinical studies on skin outcomes.
• A randomized placebo-controlled trial of exercise performance used 12 mg/day orally for 30 days in male participants.
• Randomized controlled trials examining cognitive function used doses of 6–12 mg/day for 8–12 weeks, particularly in middle-aged and older adults.
• In a male fertility study, 16 mg/day of astaxanthin was administered for three months.
• In a lipid profile assessment, 18 mg/day was evaluated in a meta-analysis of randomized controlled studies.
• Recommended or approved doses vary between countries and range between 2 and 24 mg; a review of 87 human studies found none that identified safety concerns with natural astaxanthin supplementation, including 35 studies with doses ≥12 mg/day.

Bioavailability Enhancement

In vitro bioaccessibility of raw astaxanthin oleoresin has been reported at 16%, while novel encapsulation strategies have improved this substantially. In a randomized, double-blind, crossover study in human subjects, a potato protein and olive oil formulation had a 4.8-fold higher median plasma astaxanthin AUC compared to the raw oleoresin formulation.

8. Safety Considerations and Regulatory Status

Regulatory Status

In 2010, the FDA granted "Generally Recognized As Safe (GRAS)" status to astaxanthin produced from Haematococcus pluvialis, the only current FDA-approved astaxanthin for direct human use. In the United States, astaxanthin is not approved as a food additive by the FDA and cannot be used as a colorant in conventional foods, though it may be used in some dietary supplements under different regulatory frameworks (as a dietary ingredient).

In Europe, the EFSA Panel on Nutrition, Novel Foods and Food Allergens was asked to deliver an opinion on the safety of astaxanthin when used as a novel food in food supplements at maximum levels of 8 mg/day, taking into account the overall cumulative intake of astaxanthin from all food sources. The EFSA considers the combined intake of up to 8 mg/day of astaxanthin from diet and supplements to be safe for adults, corresponding to an acceptable daily intake of 0.2 mg/kg body weight.

EFSA Acceptable Daily Intake (ADI) — Regulatory Complexity

The regulatory assessment of astaxanthin's safe dose has evolved and differs between regulatory bodies. The acceptable daily intake (ADI) of 0.2 mg astaxanthin/kg body weight per day was obtained by applying an uncertainty factor of 200 to a lowest observed adverse effect level (LOAEL) of 40 mg/kg body weight per day for the increased incidence of multinucleated hepatocytes observed in a 2-year carcinogenicity study. ATX (astaxanthin) is neither mutagenic nor carcinogenic according to the EFSA FEEDAP Panel's reassessment.

An earlier EFSA scientific opinion raised concerns that the maximum recommended intake of 4 mg astaxanthin per day and the estimated mean intake based on proposed food categories exceeded the ADI by approximately two- and three-fold, respectively, and therefore concluded that the safety of the novel food ingredients at the proposed use and use levels had not been established. Subsequent re-evaluation revised the ADI upward. An ADI of 2 mg as proposed by the EFSA was based on a toxicological study in rats using synthetic astaxanthin. However, synthetically produced astaxanthin is chemically different from natural astaxanthin, so results with synthetic astaxanthin should not be used in assessing natural astaxanthin safety.

Observed Adverse Effects and Tolerability

Clinical studies involving more than 2,000 participants report good tolerability at supplemental doses of 4–12 mg/day for periods up to one year, with no serious adverse effects observed. Most adverse events reported have been mild and gastrointestinal in nature. Skin carotenemia, a harmless condition of skin pigmentation, has been observed with high supplemental intake.

Drug Interactions

Interactions between astaxanthin and commonly used pharmacological treatments are still poorly investigated. The absorption of carotenoids is dependent on the accompanying dietary components. A high cholesterol diet may increase carotenoid absorption while a low fat diet reduces its absorption. Given astaxanthin's lipophilicity, co-administration with dietary fat consistently improves its absorption. No well-documented pharmacokinetic drug-drug interactions have been confirmed in the peer-reviewed clinical literature.

Long-Term Data Gaps

Current evidence does not sufficiently clarify astaxanthin's real bioavailability or the individual factors that influence its absorption and metabolic utilization. Long-term data are also lacking, especially regarding safety, cumulative effects, and the impact on sustained clinical outcomes. Other fields, such as dentistry and advanced cardiovascular disease, remain underexplored, limiting the understanding of its broader therapeutic potential.

Overall Evidence Assessment

There is a clear need for larger, rigorously controlled clinical trials aimed at defining optimal dosages, mechanisms of action, and real-world benefits across more diverse and representative patient populations. Preclinical (cell and animal) data for astaxanthin across multiple organ systems is extensive, but many findings have not yet been robustly replicated in human clinical trials. The antioxidant and anti-inflammatory evidence in humans is the strongest and most consistent; cardiovascular, neuroprotective, and fertility evidence remains preliminary or mixed; and overall, the compound's safety profile at commonly supplemented doses appears favorable, but regulatory bodies maintain different ADI thresholds reflecting genuine uncertainty about long-term effects.

References

• Marine-Derived Astaxanthin: Molecular Mechanisms, Biomedical Applications, and Roles in Stem Cell Biology — PMC (2025)
• Exploring the Multifunctional Benefits of Astaxanthin in Aging, Oxidative Stress, Immune Dysfunction, Gut and Skin Health — PubMed (2026)
• Astaxanthin: Structural and Functional Aspects — SciELO / Revista de Nutrição
• Astaxanthin: Sources, Extraction, Stability, Biological Activities and Its Commercial Applications — A Review — PMC (2014)
• Structures of Astaxanthin and Their Consequences for Therapeutic Application — International Journal of Food Science (2020)
• Astaxanthin as a King of Ketocarotenoids: Structure, Synthesis, Accumulation, Bioavailability and Antioxidant Properties — PMC (2023)
• Astaxanthin-Producing Green Microalga Haematococcus pluvialis: From Single Cell to High Value Commercial Products — Frontiers in Plant Science (2016)
• Astaxanthin — Wikipedia
• Haematococcus pluvialis as a Potential Source of Astaxanthin with Diverse Applications — PMC (2021)
• Astaxanthin as a Modulator of Nrf2, NF-κB, and Their Crosstalk: Molecular Mechanisms and Possible Clinical Applications — Molecules (2022)
• Astaxanthin as a Modulator of Nrf2, NF-κB — PMC full text (2022)
• The Role of Astaxanthin as an Antioxidant and Anti-Inflammatory Agent in Human Health: A Systematic Review — PMC (2025)
• Therapeutic Uses of Natural Astaxanthin: An Evidence-Based Review Focused on Human Clinical Trials — PubMed / Pharmacological Research (2021)
• Astaxanthin: A Potential Therapeutic Agent in Cardiovascular Disease — PMC (2011)
• Astaxanthin: A Compound in the Prevention of Chronic Diseases and as a Potential Adjuvant Treatment Agent — PMC (2025)
• Astaxanthin for the Food Industry — PMC (2021)
• Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging — News Medical (2026)
• Effectiveness of Dietary Supplements for Skin Photoaging in Healthy Adults: Systematic Review and Meta-Analysis — Frontiers in Medicine (2025)
• Astaxanthin Improves Aerobic Exercise Recovery Without Affecting Heat Tolerance in Humans — PMC (2020)
• Protective Effects of Astaxanthin on Skin Deterioration — PMC (2017)
• Effects of Lutein and Astaxanthin Intake on the Improvement of Cognitive Functions among Healthy Adults: Systematic Review of RCTs — PMC (2020)
• The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People — Randomized, Double-Blind, Placebo-Controlled Trial — PMC (2018)
• Safety of Astaxanthin for Its Use as a Novel Food in Food Supplements — EFSA Journal (2020)
• Call for Data Relevant to the Safety Assessment of Astaxanthin — EFSA (2018)
• Astaxanthin: How Much Is Too Much? A Safety Review — Phytotherapy Research (2019)
• Safety and Efficacy of Astaxanthin-Dimethyldisuccinate for Salmonids, Crustaceans and Other Fish — EFSA FEEDAP Panel, PMC (2020)
• Assessing the Effects of Moderate to High Dosage of Astaxanthin Supplementation on Lipid Profile Parameters — Systematic Review and Meta-Analysis — PMC (2025)
• A Systematic Review and Meta-Analysis of Astaxanthin Efficacy in Male Infertility — Scientific Reports (2026)
• Astaxanthin in Skin Health, Repair, and Disease: A Comprehensive Review — PMC (2018)
• From Nutrition to Therapeutics: The Diverse Inflammopharmacological and Biomedical Roles of Astaxanthin — PMC (2025)
• The Effect of Astaxanthin After Varicocele Surgery on Antioxidant Status and Semen Quality in Infertile Men: A Triple-Blind Randomized Clinical Trial — PMC (2024)
• Evaluating Astaxanthin Bioavailability and a New Technology for Improving It — ClinicalTrials.gov NCT04583722